Adrian Ivanoiu

List of Publications by Year
in descending order

59 papers	3,797 citations	304743 22 h-index	189892 50 g-index
62 all docs	62 docs citations	62 times ranked	6163 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	[18]F‑flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	5.3	582
3	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	9.0	512
4	Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. Journal of Neurology, 2021, 268, 751-757.	3.6	154
5	Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer?s disease. Journal of Neurology, 2005, 252, 47-55.	3.6	135
6	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
7	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
8	*TBK1* Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
9	Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurology, 2018, 75, 1114.	9.0	75
10	Patterns of impairment in autobiographical memory in the degenerative dementias constrain models of memory. Neuropsychologia, 2006, 44, 1936-1955.	1.6	70
11	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
12	Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. NeuroImage, 2013, 64, 517-525.	4.2	56
13	Clinical Evidence of Disease Anticipation in Families Segregating a *C9orf72* Repeat Expansion. JAMA Neurology, 2017, 74, 445.	9.0	56
14	Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase, 2005, 11, 32-39.	0.6	55
15	Associative encoding deficits in amnestic mild cognitive impairment: A volumetric and functional MRI study. NeuroImage, 2011, 56, 1743-1748.	4.2	34
16	Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis. Journal of Neurology, 2019, 266, 2304-2311.	3.6	34
17	A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology. Frontiers in Neurology, 2018, 9, 384.	2.4	33
18	NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiology of Aging, 2018, 61, 255.e1-255.e7.	3.1	32

#	Article	IF	Citations
19	Classification of Non-Demented Patients Attending a Memory Clinic using the New Diagnostic Criteria for Alzheimer's Disease with Disease-Related Biomarkers. Journal of Alzheimer's Disease, 2014, 43, 835-847.	2.6	29
20	Retrieval of Episodic and Semantic Autobiographical Memories in Early Alzheimer's Disease and Semantic Dementia. Cortex, 2004, 40, 173-175.	2.4	28
21	Impaired spontaneous belief inference following acquired damage to the left posterior temporoparietal junction. Social Cognitive and Affective Neuroscience, 2016, 11, 1513-1520.	3.0	28
22	Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 302-310.	6.4	23
23	Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 49, 271-276.	2.6	22
24	Dramatic impairment of prediction due to frontal lobe degeneration. Journal of Neurophysiology, 2012, 108, 2957-2966.	1.8	21
25	Is 18F-Flutemetamol PET/CT Able to Reveal Cardiac Amyloidosis?. Clinical Nuclear Medicine, 2014, 39, 747-749.	1.3	19
26	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
27	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. Neurobiology of Aging, 2018, 67, 84-94.	3.1	17
28	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimerâ€™s Disease (REMEMBER). Journal of Alzheimer's Disease, 2018, 63, 1509-1522.	2.6	17
29	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
30	Alzheimerâ€™s disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica, 2017, 117, 811-819.	1.1	15
31	A case study about the interplay between language control and cognitive abilities in bilingual differential aphasia: Behavioral and brain correlates. Journal of Neurolinguistics, 2018, 46, 37-68.	1.1	15
32	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
33	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. Journal of Alzheimer's Disease, 2019, 69, 989-1001.	2.6	14
34	Increased sensitivity to proactive interference in amnestic mild cognitive impairment is independent of associative and semantic impairment. Brain and Cognition, 2010, 72, 325-331.	1.8	13
35	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	5.2	13
36	Performance on the RI-48 Cued Recall Test Best Predicts Conversion to Dementia at the 5- and 10-Year Follow-Ups. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 258-266.	1.3	12

#	Article	IF	Citations
37	Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 253-270.	2.6	12
38	Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2016, 22, 991-1004.	1.8	11
39	Neuralgic amyotrophy associated with hepatitis E virus (HEV) infection: a case report. Acta Neurologica Belgica, 2017, 117, 555-557.	1.1	10
40	Increased sensitivity to proactive and retroactive interference in amnestic mild cognitive impairment: New insights. Brain and Cognition, 2012, 80, 104-110.	1.8	9
41	Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved. Journal of Alzheimer's Disease, 2016, 53, 651-660.	2.6	9
42	Choreoathetotic syndrome following cardiac surgery. Journal of Clinical Anesthesia, 2017, 36, 59-61.	1.6	9
43	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. Acta Neurologica Belgica, 2015, 115, 547-555.	1.1	7
44	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. Journal of Alzheimer's Disease, 2021, 83, 623-639.	2.6	7
45	Investigating Associative Learning Effects in Patients with Prodromal Alzheimer's Disease Using the Temporal Context Model. Journal of the International Neuropsychological Society, 2015, 21, 699-708.	1.8	5
46	Spouse-Appraised Memory Functioning Predicts Memory Decline Better Than Subjective Memory Complaints in Community Dwelling Older Adults at Genetic Risk for Alzheimer's Disease. Frontiers in Psychiatry, 2021, 12, 633102.	2.6	4
47	Infliximab for relapsing neurosarcoidosis recurring after kidney transplantation: a case report. Acta Clinica Belgica, 2021, 76, 149-151.	1.2	3
48	Frontotemporal dementia patients exhibit deficits in predictive saccades. Journal of Computational Neuroscience, 2021, 49, 357-369.	1.0	2
49	Multivariate prediction of rate of decline in memory functioning over six years using imaging biomarkers. Alzheimer's and Dementia, 2020, 16, e045645.	0.8	1
50	NEURO-IMAGE: MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.1	1
51	O2-03-02: REGIONAL BRAIN METABOLISM AND CORTICAL THICKNESS IN F18-FLUTEMETAMOL AMYLOID-POSITIVE VERSUS -NEGATIVE MILD COGNITIVE IMPAIRMENT PATIENTS. , 2014, 10, P167-P168.		0
52	[P3–461]: IMPROVED PREDICTION OF COGNITIVE PERFORMANCE USING A WEIGHTED LINEAR COMPOSITE OF BIOMARKERS OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1149.	0.8	0
53	Spouse-appraised memory functioning predicts memory decline better than subjective memory complaints in non-demented older adults. Alzheimer's and Dementia, 2020, 16, e040898.	0.8	0
54	Alzheimer-like glucose hypometabolism predicts subsequent dementia in amyloid-negative mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e044541.	0.8	0

#	Article	IF	Citations
55	CSF biomarkers within a Belgian allochthonous population. Alzheimer's and Dementia, 2020, 16, e047125.	0.8	0
56	lncRNAs as a novel source of diagnostic applications for early Alzheimer's disease and other dementia types. Alzheimer's and Dementia, 2020, 16, e039788.	0.8	0
57	Correlation between MKâ€6240 tauâ€PET and CSF tau, Pâ€tau and amyloid proteins. Alzheimer's and Dementia, 2021, 17, .	0.8	0
58	Increased intraâ€network functional connectivity in MCI patients progressing towards dementia compared to stable MCI. Alzheimer's and Dementia, 2021, 17, .	0.8	0
59	Pattern separation and pattern completion for human face identity recognition in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0